Possible association of hepatitis C virus infection with late-onset psoriasis: A hospital-based observational study

Journal of Dermatology

Volumn 40, Issue 10, 2013, Pages 813-818

  Imafuku, Shinichi ^a   Naito, Reiko ^a   Nakayama, Juichiro ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

epidemiology; hepatitis C virus; metabolic syndrome; psoriasis; tumor necrosis factor alpha

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CHRONIC INFLAMMATION; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FAMILY HISTORY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PSORIASIS; SEX DIFFERENCE; SKIN EXAMINATION;

EPIDEMIOLOGY; HEPATITIS C VIRUS; METABOLIC SYNDROME; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; BODY MASS INDEX; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; FEMALE; HEPATITIS C; HUMANS; HYPERTENSION; INFANT; JAPAN; MALE; MIDDLE AGED; PSORIASIS; SEX RATIO; YOUNG ADULT;

EID: 84885187774     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/1346-8138.12240     Document Type: Article

References (39)

1. Takahashi H, Tsuji H, Takahashi I, Shibaki H, Ishida-Yamamoto A, Iizuka H,. Prevalence of obesity/adiposity in Japanese psoriasis patients: adiposity is correlated with the severity of psoriasis. J Dermatol Sci 2009; 55: 74-76.
2. Love TJ, Qureshi AA, Karlson EW, Gelfand JM, Choi H,. Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006. Arch Dermatol 2011; 147: 419-424.
3. Rosa DJ, Machado RF, Matias FA, et al,. Influence of severity of the cutaneous manifestations and age on the prevalence of several cardiovascular risk factors in patients with psoriasis. J Eur Acad Dermatol Venereol 2011; 26: 348-353.
4. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB,. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-1741.
5. Boehncke WH, Boehncke S, Tobin AM, Kirby B,. The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 2011; 20: 303-307.
6. Ide T, Hino T, Ogata K, et al,. A randomized study of extended treatment with peginterferon alpha-2b plus ribavirin based on time to HCV RNA negative-status in patients with genotype 1b chronic hepatitis C. Am J Gastroenterol 2009; 104: 70-75.
7. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL,. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000; 133: 592-599.
8. Knobler H, Schihmanter R, Zifroni A, Fenakel G, Schattner A,. Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc 2000; 75: 355-359.
9. Eslam M, Khattab MA, Harrison SA,. Insulin resistance and hepatitis C: an evolving story. Gut 2011; 60: 1139-1151.
10. Siegel AB, Zhu AX,. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer 2009; 115: 5651-5661.
11. Kanazawa K, Aikawa T, Tsuda F, Okamoto H,. Hepatitis C virus infection in patients with psoriasis. Arch Dermatol 1996; 132: 1391-1392.
12. Chouela E, Abeldano A, Panetta J, et al,. Hepatitis C virus antibody (anti-HCV): prevalence in psoriasis. Int J Dermatol 1996; 35: 797-799.
13. Taglione E, Vatteroni ML, Martini P, et al,. Hepatitis C virus infection: prevalence in psoriasis and psoriatic arthritis. J Rheumatol 1999; 26: 370-372.
14. Yamamoto T, Yokozeki H, Nishioka K,. Evaluation of psoriatic patients with HCV infection. J Dermatol 2005; 32: 769-770.
15. Cohen AD, Weitzman D, Birkenfeld S, Dreiher J,. Psoriasis associated with hepatitis C but not with hepatitis B. Dermatology 2010; 220: 218-222.
16. Imafuku S, Nakayama J,. Questionnaire-based survey of the treatment of patients with psoriasis and hepatitis C in Japan. J Eur Acad Dermatol Venereol 2010; 24: 1114-1116.
17. Imafuku S, Nakayama J,. Profile of patients with psoriasis associated with hepatitis C virus infection. J Dermatol 2013; 40: 428-433.
18. Knobler H, Schattner A,. TNF-{alpha}, chronic hepatitis C and diabetes: a novel triad. QJM 2005; 98: 1-6.
19. Knobler H, Zhornicky T, Sandler A, Haran N, Ashur Y, Schattner A,. Tumor necrosis factor-alpha-induced insulin resistance may mediate the hepatitis C virus-diabetes association. Am J Gastroenterol 2003; 98: 2751-2756.
20. Aytug S, Reich D, Sapiro LE, Bernstein D, Begum N,. Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology 2003; 38: 1384-1392.
21. Zylberberg H, Rimaniol AC, Pol S, et al,. Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. J Hepatol 1999; 30: 185-191.
22. Zein NN,. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005; 42: 315-322.
23. Wozniak SE, Gee LL, Wachtel MS, Frezza EE,. Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci 2009; 54: 1847-1856.
24. Mathieu P, Lemieux I, Despres JP,. Obesity, inflammation, and cardiovascular risk. Clin Pharmacol Ther 2010; 87: 407-416.
25. Lumeng CN, Saltiel AR,. Inflammatory links between obesity and metabolic disease. J Clin Invest 2011; 121: 2111-2117.
26. Stanley TL, Zanni MV, Johnsen S, et al,. TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J Clin Endocrinol Metab 2011; 96: E146-E150.
27. Pappa T, Alevizaki M,. Endogenous sex steroids and cardio- and cerebro-vascular disease in the postmenopausal period. Eur J Endocrinol 2012; 167: 145-156.
28. Hari P, Nerusu K, Veeranna V, et al,. A gender-stratified comparative analysis of various definitions of metabolic syndrome and cardiovascular risk in a multiethnic U.S. population. Metab Syndr Relat Disord 2012; 10: 47-55.
29. Kawada A, Tezuka T, Nakamizo Y, et al,. A survey of psoriasis patients in Japan from 1982 to 2001. J Dermatol Sci 2003; 31: 59-64.
30. Takahashi H, Nakamura K, Kaneko F, Nakagawa H, Iizuka H,. Analysis of psoriasis patients registered with the Japanese Society for Psoriasis Research from 2002-2008. J Dermatol 2011; 38: 1125-1129.
31. Tanaka J, Kumagai J, Katayama K, et al,. Sex- and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3,485,648 first-time blood donors during 1995-2000. Intervirology 2004; 47: 32-40.
32. Tanaka J, Kumada H, Ikeda K, et al,. Natural histories of hepatitis C virus infection in men and women simulated by the Markov model. J Med Virol 2003; 70: 378-386.
33. Tanaka J, Katayama K,. Hepatitis C virus infection in japan-epidemiology. Nihon Rinsho 2011; 69 (Suppl 4): 15-22.
34. Everhart JE, Lok AS, Kim HY, et al,. Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology 2009; 137: 549-557.
35. Wolk K, Mallbris L, Larsson P, Rosenblad A, Vingard E, Stahle M,. Excessive body weight and smoking associates with a high risk of onset of plaque psoriasis. Acta Derm Venereol 2009; 89: 492-497.
36. Gisondi P, Del Giglio M, Di Francesco V, Zamboni M, Girolomoni G,. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr 2008; 88: 1242-1247.
37. Chandran V, Raychaudhuri SP,. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 2010; 34: J314-J321.
38. Gudjonsson JE, Elder JT,. Psoriasis: epidemiology. Clin Dermatol 2007; 25: 535-546.
39. Tsai T-F, Wang T-S, Hung S-T, et al,. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci 2011; 63: 40-46.